TVTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TVTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Travere Therapeutics's EBITDA for the three months ended in Sep. 2024 was $-52.1 Mil. Travere Therapeutics's Revenue for the three months ended in Sep. 2024 was $62.9 Mil. Therefore, Travere Therapeutics's EBITDA margin for the quarter that ended in Sep. 2024 was -82.77%.
The historical data trend for Travere Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EBITDA Margin % | Get a 7-Day Free Trial | -61.15 | -73.19 | -139.91 | -273.54 | -224.63 |
Travere Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EBITDA Margin % | Get a 7-Day Free Trial | -202.00 | -169.15 | -297.50 | -123.40 | -82.77 |
For the Biotechnology subindustry, Travere Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Travere Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Travere Therapeutics's EBITDA Margin % falls into.
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Travere Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
Travere Therapeutics's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics (NAS:TVTX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Thank you for viewing the detailed overview of Travere Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sandra Calvin | officer: VP, Corp Controller and CAO | 3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130 |
Gary A Lyons | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Jeffrey A Meckler | director | 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003 |
Jula Inrig | officer: Chief Medical Officer | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
William E. Rote | officer: Senior Vice President, R&D | C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Christopher R. Cline | officer: Chief Financial Officer | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130 |
Eric M Dube | director, officer: Chief Executive Officer | 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Peter Heerma | officer: Chief Commercial Officer | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
Elizabeth E Reed | officer: SVP, GC & Corporate Secretary | 9050 CAMINO SANTA FE, SAN DIEGO CA 92121 |
Laura Clague | officer: Chief Financial Officer | 370 PARK RANCH PLACE, ESCONDIDO CA 92025 |
Steve Aselage | director | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Brinkley Ruth Williams | director | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
Noah L. Rosenberg | officer: Chief Medical Officer | C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170 |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
Neil F. Mcfarlane | officer: Chief Operating Officer | C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
From GuruFocus
By GuruFocus News • 10-31-2024
By GuruFocus News • 11-05-2024
By PRNewswire • 10-25-2024
By PRNewswire • 11-02-2024
By GuruFocus News • 11-09-2024
By GuruFocus News • 11-14-2024
By GuruFocus News • 11-01-2024
By PRNewswire • 11-19-2024
By Marketwired • 11-08-2024
By GuruFocus News • 11-01-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.